IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Webhead who wrote (301)	1/22/1997 7:17:00 PM
From: Brad C. Dunlap	of 1762

Hi ECG, well since you asked, I believe that the future of Idec is their primatized antibodies. This is not to take anything away from C2B8[chimeric] which I believe will generate hundreds of millions of dollars in revenue. The potential of Idec's primatized antibodies that are so unique and to be used successfully in chronic diseases is huge. CE9.1 is the first real test of Idec's primatized antibodies and so far the results for rheumatoid arthritis are extremely impressive. Later this year when CE9.1 phase III results are released, and if successfull will not only add value to Idec for RA but also for the many other applications that the primatized antibodies will be targeted against. This is the real value in Idec and due to the success of C2B8 it has been somewhat overlooked.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next